RenovoRx, Inc.

Equities

RNXT

US75989R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.243 ^USD	+2.73%		+6.24%	-45.72%

Apr. 16	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
Apr. 15	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer

February 09, 2024 at 04:31 pm EST

On February 5, 2024, James Ahlers provided written notice to RenovoRx, Inc. (the ?Company?) of his resignation as the Company?s Chief Financial Officer, effective immediately. Mr. Ahlers resignation was for personal reasons and not as a result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.

Latest news about RenovoRx, Inc.

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	Apr. 16	CI
RenovoRx, Inc. announced that it has received $11.136652 million in funding	Apr. 14	CI
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding	Apr. 03	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	Feb. 23	CI
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	Feb. 09	CI
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer	Feb. 09	CI
Alliance Global Starts RenovoRx With Buy Rating, $4 Price Target	Feb. 02	MT
RenovoRx Raises $6.1 Million From Private Placement; Shares Rise	Jan. 29	MT
RenovoRx, Inc. announced that it has received $6.111696 million in funding	Jan. 25	CI
Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee	Jan. 02	CI
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	Dec. 21	CI
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	Dec. 13	CI
Renovorx Appoints Michel Ducreux as Scientific Advisory Board	Nov. 16	CI
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Maxim Downgrades RenovoRx to Hold From Buy	Nov. 15	MT
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Roth MKM Adjusts Price Target on RenovoRx to $13 From $14, Maintains Buy Rating	23-08-18	MT
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	23-07-20	CI
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	23-06-29	CI
Top Premarket Gainers	23-06-28	MT
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell 3000E Index	23-06-23	CI
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell Microcap Index	23-06-23	CI
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell Microcap Growth Index	23-06-23	CI

Chart RenovoRx, Inc.

Duration

Period

More charts

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapyâs toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.243 USD

Average target price

3.75 USD

Spread / Average Target

+201.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVORX, INC.	-45.72%	29.77M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs